← FDA DRUG APPROVALS

FDA ANDA · ANDA040872

PHENTERMINE RESIN COMPLEX

Sponsor: LANNETT CO INC

APPLICATION
ANDA040872
TYPE
ANDA
ORIGINAL APPROVAL
2011-07-28
LATEST ACTION
2017-05-31
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

PHENTERMINE RESIN COMPLEXDiscontinued
PHENTERMINE RESIN COMPLEX EQ 30MG BASE · CAPSULE, EXTENDED RELEASE · ORAL
PHENTERMINE RESIN COMPLEXDiscontinued
PHENTERMINE RESIN COMPLEX EQ 15MG BASE · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2017-05-31Labeling · Supplement 3 · standardAP
2012-12-06Labeling · Supplement 1 · standardAP
2011-07-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →